# Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
Canonical URL: https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-host-webcast-highlighting-presentations-on-enzyme-transpo-bec4b7df
Ticker: DNLI
Company: Denali Therapeutics
Source: Denali Therapeutics
Published: 2026-02-02 13:00 EST
## Summary

Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live...

## Article Body
Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™ (ETV) programs at the upcoming 22nd Annual WORLD Symposium ™ being held February 2-6, 2026, in San Diego, California. These presentations will demonstrate the broad potential of the ETV to enable the delivery of enzyme replacement therapies to the whole body, including the brain. Titles and times for the presentations were previously announced in a corporate news release here . The live webcast will begin at 12:30 p.m. Pacific Time on Thursday, February 5, 2026, and can be accessed on the Events page of the Investor section on Denali’s corporate website at https://investors.denalitherapeutics.com/events or click here .

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform the lives of people living with neurodegenerative, lysosomal storage and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Investor Contact: Laura Hansen, Ph.D. hansen@dnli.com

Media Contact: Erin Patton epatton@dnli.com
## Recent Company News
- 2026-07-27 20:01 EST — [Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026](https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-report-second-quarter-2026-financial-results-and-business-55ac999b) — Source: Denali Therapeutics
- 2026-07-09 20:01 EST — [Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier](https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-give-opening-plenary-address-at-alzheimer-s-association-i-4deb6898) — Source: Denali Therapeutics
- 2026-06-18 12:00 EST — [Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million](https://biopharmsignal.com/news/DNLI/denali-therapeutics-enters-agreement-to-sell-rare-pediatric-disease-priority-rev-0e62f7af) — Source: Denali Therapeutics
- 2026-05-21 22:00 EST — [Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease](https://biopharmsignal.com/news/DNLI/biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122--cfdf22fe) — Source: Denali Therapeutics
- 2026-05-07 20:01 EST — [Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-first-quarter-2026-financial-results-and-business-hi-b2e6c27c) — Source: Denali Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)